Biotech · Private company
Viridian Therapeutics, Inc.
Track this companyFree. Adds Viridian Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials94 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- AutoinjectorPhase 3 · Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VeligrotugPhase 3 · Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VRDN-003Phase 3 · Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VRDN-003Phase 3 · Thyroid Eye Disease (TED)ClinicalTrials.gov · fetched Nov 12, 2026
- veligrotrug (LUMVOA™)Thyroid Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabPHASE4 · NOT_YET_RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07832136 · fetched Nov 12, 2026
- A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)PHASE3 · COMPLETED · started Jul 1, 2025ClinicalTrials.gov NCT07155668 · fetched Nov 12, 2026
- A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 3, 2025ClinicalTrials.gov NCT06812325 · fetched Nov 12, 2026
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 27, 2024ClinicalTrials.gov NCT06625398 · fetched Nov 12, 2026
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 27, 2024ClinicalTrials.gov NCT06625411 · fetched Nov 12, 2026
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)PHASE3 · COMPLETED · started May 23, 2024ClinicalTrials.gov NCT06384547 · fetched Nov 12, 2026
- An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301PHASE3 · COMPLETED · started Jan 31, 2024ClinicalTrials.gov NCT06179875 · fetched Nov 12, 2026
- An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)PHASE3 · COMPLETED · started Nov 1, 2023ClinicalTrials.gov NCT06021054 · fetched Nov 12, 2026
- A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)PHASE3 · COMPLETED · started Nov 16, 2022ClinicalTrials.gov NCT05176639 · fetched Nov 12, 2026